No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
nivolumab
Bristol-Myers Squibb Press Release - 2 days
|
HER-2 Negative + PD-L1 expression
HER-2 Negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab
Merck (MSD) Press Release - 4 weeks
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab + ramucirumab + ALX148
Sensitive: C3 – Early Trials
ESMO-GI 2021 - 4 weeks
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Trazimera (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Herzuma (trastuzumab biosimilar)
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Zercepac (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ontruzant (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Kanjinti (trastuzumab biosimilar)
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Ogivri (trastuzumab biosimilar)
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
DOF
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
TCF
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
FP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
CaT
Sensitive: A2 - Guideline
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
CAPOX
Sensitive: A2 - Guideline
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
FP
Sensitive: A2 - Guideline
|
HER-2 Negative + PD-L1 expression
HER-2 Negative + PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
nivolumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
DP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
FLOT
Sensitive: A2 - Guideline
|
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
docetaxel + irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
IP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
capecitabine + oxaliplatin
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
entrectinib
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
HER2 inhibitor
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
oxaliplatin
Sensitive: A2 - Guideline
|
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel + capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
FOLFOX
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
carboplatin + 5-fluorouracil + docetaxel
Sensitive: A2 - Guideline
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab + pertuzumab
Sensitive: B - Late Trials
|
FGFR2b overexpression + HER2 negative
FGFR2b overexpression + HER2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
FPA-144
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
nivolumab
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Immunotherapy
Sensitive: B - Late Trials
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
nivolumab
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
avelumab
Sensitive: B - Late Trials
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
ramucirumab
Sensitive: B - Late Trials
|
MET expression
MET expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
AMG 102
Resistant: B - Late Trials
|
MET amplification
MET amplification
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
AMG 102
Resistant: B - Late Trials
|
HER-2 amplification
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab
Sensitive: B - Late Trials
|
DKK1 overexpression
DKK1 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
DKN-01
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
nivolumab + ipilimumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
durvalumab
Resistant: C1 - Off-label
|
HER-2 amplification
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
paclitaxel
Sensitive: C2 – Inclusion Criteria
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
PRS-343
Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
rivoceranib
Sensitive: C2 – Inclusion Criteria
|
HER-2 underexpression
HER-2 underexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
|
HER-2 expression
HER-2 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
HER-2 mutation
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + margetuximab
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
|
CLDN18.2 expression
CLDN18.2 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
IMAB362
Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
camrelizumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 negative
HER-2 negative
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
rivoceranib + camrelizumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
HER-2 overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
Her-VAXX
Sensitive: C2 – Inclusion Criteria
|
FGFR2b overexpression
FGFR2b overexpression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
FPA-144
Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression + PTEN deletion
HER-2 overexpression + PTEN deletion
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab
Resistant: C3 – Early Trials
|
FGFR2b expression
FGFR2b expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
FPA-144
Sensitive: C3 – Early Trials
|
HER-2 expression + TMB-H
HER-2 expression + TMB-H
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab
Sensitive: C3 – Early Trials
|
HER-2 expression + HER-2 L869R
HER-2 expression + HER-2 L869R
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab
Resistant: C3 – Early Trials
|
HER-2 expression + HER-2 D769H
HER-2 expression + HER-2 D769H
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab
Resistant: C3 – Early Trials
|
HER-2 expression + HER-2 amplification
HER-2 expression + HER-2 amplification
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + trastuzumab
Sensitive: C3 – Early Trials
|
HER-2 positive
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
carboplatin
Sensitive: C3 – Early Trials
|
PD-L1 expression
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + ramucirumab
Sensitive: C3 – Early Trials
|
